GlaxoSmithKline Pharmaceuticals saw its stock price climb to a fresh 52-week high during the trading session on June 4, 2025, with shares rising 5.04% to ₹3,408.50 on the NSE. This gain placed it among the leading performers in the NIFTY MIDCAP 150 index, reflecting strong investor confidence.

The company’s recent quarterly financial results underscore steady growth. For the quarter ended March 2025, consolidated revenue stood at ₹974.37 crore, up from ₹949.42 crore in December 2024 and showing a steady rise compared to previous quarters. Net profit for the quarter increased to ₹262.87 crore from ₹229.88 crore in the previous quarter. Earnings per share (EPS) also improved to ₹15.52 from ₹13.57 in December 2024.

On an annual basis, GlaxoSmithKline Pharmaceuticals has demonstrated a solid upward trajectory. Revenue grew from ₹2,925.60 crore in 2021 to ₹3,749.21 crore in 2025, while net profit surged from ₹287.27 crore to ₹927.58 crore during the same period. EPS nearly doubled from ₹31.35 in 2021 to ₹54.52 in 2025. Key financial ratios further highlight the company’s robust fundamentals, with a return on equity (ROE) of 47.53% and zero debt-to-equity ratio, indicating a strong and debt-free balance sheet.

The strong financial performance coupled with positive market sentiment, as per Moneycontrol’s June 4, 2025 analysis, contributed to the stock’s breakout to a new high. Investors appear bullish on GlaxoSmithKline Pharma’s growth prospects, supported by consistent operational execution and expanding profitability.